Tolterodine and its active 5-hydroxymethyl metabolite: Pure muscarinic receptor antagonists

Pharmacology and Toxicology

Volumn 90, Issue 5, 2002, Pages 260-267

  Nilvebrant, Lisbeth ^a  

^a Nilvebrant Pharma Consulting AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ATROPINE; DILTIAZEM; HALOPERIDOL; HISTAMINE RECEPTOR; MEPYRAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; N,N DIISOPROPYL 3 (2 HYDROXY 5 HYDROXYMETHYLPHENYL) 3 PHENYLPROPANAMINE; NIFEDIPINE; OXYBUTYNIN; PHENTOLAMINE; PROMETHAZINE; TOLTERODINE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; GUINEA PIG; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BENZHYDRYL COMPOUNDS; CRESOLS; GUINEA PIGS; HEART ATRIA; ILEUM; MALE; MUSCARINIC ANTAGONISTS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; MYOCARDIAL CONTRACTION; PAPILLARY MUSCLES; PHENYLPROPANOLAMINE; PORTAL VEIN; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER;

ANIMALIA; CAVIA PORCELLUS; SUS SCROFA;

EID: 0036257953     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2002.900506.x     Document Type: Article

References (55)

1. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder
2. Current concepts in the treatment of disorders of micturition
3. The pharmacology of lower urinary tract smooth muscles and penile erectile tissues
4. Pharmacological treatment of urinary incontinence
5. Torsades de pointes and terodiline
6. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
7. 3H]-(+)-pentazocine: A potent and highly selective benzomorphan-based probe for sigma-1 receptors
8. Pharmacokinetics and pharmacodynamics of tolterodine in man: A new drug for the treatment of urinary bladder overactivity
9. "Calcium antagonists": A class of drugs with a bright future. Part I. Cellular calcium homeostasis and calcium as a coupling messenger
10. Tolterodine once-daily: Selectivity for the bladder over effects on salivation compared to Ditropan XL
11. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
12. Torsades de pointes ventricular tachycardia and terodiline
13. 3H]-mepyramine binding sites in guinea pig cerebellum and lung
14. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder
15. Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle
16. Pharmacological in vitro and in vivo profile of DD 01 - A major metabolite of tolterodine
17. A comparison of several calcium antagonists on uterine, vascular and cardiac muscles from the rat
18. 3H]-prazosin to rat brain α-adrenergic receptors
19. On the pharmacokinetics of propiverine in man
20. Measurement of oxybutynin and its desethyl metabolite in plasma, and its application to studies in young, elderly and frail elderly volunteers
21. R and S enantiomers of oxybutynin: Pharmacological effects in guinea pig bladder and intestine
22. Effects of propiverine hydrochloride (propiverine) on isolated rat and dog urinary bladder
23. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance
24. Tolterodine in the treatment of overactive bladder: Analysis of the pooled phase II efficacy and safety data
25. 3H](+)PN 200-110 binding to dihydropyridine receptors associated with calcium channels in rat cerebral cortex and heart
26. The efficacy, tolerability and safety profile of tolterodine in the treatment of overactive/unstable bladder
27. Torsades de pointes complicating treatment with terodiline
28. Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine
29. Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders
30. Cardiac versus vascular effects of a new dihydropyridine derivative, CV-4093
31. The mechanism of action of tolterodine
32. Clinical experiences with tolterodine
33. Tolterodine - A new bladder-selective antimuscarinic agent
34. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine
35. The in vitro pharmacological profile of tolterodine - New agent for the treatment of urinary urge incontinence
36. Tolterodine - A new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data
37. Enantiomers of oxybutynin: In vitro pharmacological characterization at M1, M2 and M3 receptors and in vivo effects on urinary bladder contraction, mydriasis and salivation in guinea pigs
38. SR 33557, a novel calcium entry blocker. I. In vitro isolated tissue studies
39. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes
40. Serum protein binding of tolterodine and its major metabolites in humans and several animal species
41. 3 receptors
42. 125I]iodinated probes
43. Negative inotropic properties of isradipine, nifedipine, diltiazem and verapamil in dissected human myocardial tissue
44. Anticholinergic properties of propiverine and its metabolites
45. Comparison of the antimuscarinic and the antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of terodiline
46. Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor overactivity
47. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval
48. Inhibitory effects of propiverine on rat and guinea-pig urinary bladder muscle
49. 3H-RX821001 ligand binding
50. Omega-conotoxin GVIA binding to high-affinity receptor in brain: Characterization, calcium sensitivity and solubilisation
51. Comparison of oxybutynin and its active metabolite in the human detrusor and parotid gland
52. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability
53. Pharmacological effects of tolterodine on human isolated urinary bladder